WallStSmart

Anheuser Busch Inbev NV ADR (BUD)vsConstellation Brands Inc Class A (STZ)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Anheuser Busch Inbev NV ADR generates 549% more annual revenue ($59.32B vs $9.14B). STZ leads profitability with a 18.5% profit margin vs 11.5%. BUD appears more attractively valued with a PEG of 1.72. BUD earns a higher WallStSmart Score of 61/100 (C+).

BUD

Buy

61

out of 100

Grade: C+

Growth: 6.0Profit: 6.5Value: 4.7Quality: 5.0

STZ

Buy

56

out of 100

Grade: C

Growth: 2.0Profit: 8.5Value: 5.0Quality: 5.5
Piotroski: 6/9Altman Z: 1.95
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BUDOvervalued (-12.7%)

Margin of Safety

-12.7%

Fair Value

$68.57

Current Price

$75.55

$6.98 premium

UndervaluedFair: $68.57Overvalued

Intrinsic value data unavailable for STZ.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BUD4 strengths · Avg: 8.8/10
EPS GrowthGrowth
63.3%10/10

Earnings expanding 63.3% YoY

Market CapQuality
$140.73B9/10

Large-cap with strong market position

Operating MarginProfitability
24.9%8/10

Strong operational efficiency at 24.9%

Free Cash FlowQuality
$9.89B8/10

Generating 9.9B in free cash flow

STZ3 strengths · Avg: 8.3/10
Return on EquityProfitability
22.6%9/10

Every $100 of equity generates 23 in profit

P/E RatioValuation
15.9x8/10

Attractively priced relative to earnings

Operating MarginProfitability
26.7%8/10

Strong operational efficiency at 26.7%

Areas to Watch

BUD3 concerns · Avg: 4.0/10
PEG RatioValuation
1.724/10

Expensive relative to growth rate

Price/BookValuation
10.1x4/10

Trading at 10.1x book value

Revenue GrowthGrowth
4.8%4/10

4.8% revenue growth

STZ4 concerns · Avg: 2.8/10
Altman Z-ScoreHealth
1.954/10

Grey zone — moderate risk

Debt/EquityHealth
1.383/10

Elevated debt levels

PEG RatioValuation
2.832/10

Expensive relative to growth rate

Revenue GrowthGrowth
-11.3%2/10

Revenue declined 11.3%

Comparative Analysis Report

WallStSmart Research

Bull Case : BUD

The strongest argument for BUD centers on EPS Growth, Market Cap, Operating Margin.

Bull Case : STZ

The strongest argument for STZ centers on Return on Equity, P/E Ratio, Operating Margin. Profitability is solid with margins at 18.5% and operating margin at 26.7%.

Bear Case : BUD

The primary concerns for BUD are PEG Ratio, Price/Book, Revenue Growth.

Bear Case : STZ

The primary concerns for STZ are Altman Z-Score, Debt/Equity, PEG Ratio.

Key Dynamics to Monitor

BUD profiles as a value stock while STZ is a declining play — different risk/reward profiles.

BUD carries more volatility with a beta of 0.79 — expect wider price swings.

BUD is growing revenue faster at 4.8% — sustainability is the question.

BUD generates stronger free cash flow (9.9B), providing more financial flexibility.

Bottom Line

BUD scores higher overall (61/100 vs 56/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Anheuser Busch Inbev NV ADR

CONSUMER DEFENSIVE · BEVERAGES - BREWERS · USA

Anheuser-Busch InBev SA / NV is engaged in the production, distribution and sale of beer, alcoholic beverages and soft drinks worldwide.

Constellation Brands Inc Class A

CONSUMER DEFENSIVE · BEVERAGES - BREWERS · USA

Constellation Brands, Inc., headquartered in Victor, New York, is an American producer and marketer of beer, wine, and spirits.

Visit Website →

Want to dig deeper into these stocks?